• Orange Dental

  Participated · Series B · Jan 2024

  On February 24, 2021, 依生生物制药有限公司 announced completion of a Series B financing of more than $130 million. The round was co‑led by Oceanpine Capital (海松资本) and OrbiMed (奥博资本). Following the transaction, the company's institutional investor base included Oceanpine, OrbiMed, 斯道资本, F‑Prime Capital, 3W Capital, 高瓴资本, Adjuvant Capital, 和玉资本, AIHC, 益普资本, Superstring Capital and 海通国际. 易凯资本 served as the company's exclusive financial adviser on the deal. The financing expanded the company's investor roster and represents a significant recapitalization event at the B‑round stage. No additional product, operational or use‑of‑proceeds details for the company were provided in the articles.

• OPay

  Participated · Series C · Aug 2021

  OPay operates a mobile money and payments platform focused on serving unbanked and underbanked users via a network of thousands of agents. Its core revenue and usage drivers are person-to-person transfers, bill payments, and nonmerchant point-of-sale transactions. The company has expanded beyond an exclusive Nigerian presence into Egypt as an entry point to the Middle East. OPay reports very large transaction volumes: Opera said monthly transactions grew 4.5x to over $2 billion in December, and Bloomberg reported monthly volumes exceed $3 billion. The company claims to process about 80% of bank transfers among mobile money operators in Nigeria and 20% of the country’s nonmerchant POS transactions. OPay has pursued an international money transfer license and is reported to be working on a WorldRemit partnership. OPay is an Africa-focused fintech startup founded by Opera in 2018 and based in Lagos. It operates a payments product and a suite of consumer services in Nigeria, including ride-hail ORide, food delivery OFood and OLeads for SME marketing. The company focuses on high-frequency use cases such as transportation, food services and other daily activities, while also facilitating bill payments and airtime purchases. Since its Series A raise, OPay says it has scaled to 140,000 active agents and handles $10 million in daily transaction volume. OPay will use new funding to scale further in Nigeria, expand its payments product to Kenya, Ghana and South Africa, and deploy capital across Opera’s Africa network. Opera’s support positions OPay as part of a broader push to build a multi-service commercial internet platform across the continent. OPay offers a mobile payments and digital-finance platform that serves Nigeria and supports Opera’s broader commercial services. The company was founded by Opera in 2018 and grew out of Opera’s browser popularity in Africa. OPay has scaled to roughly 40,000 active agents and processes about $5 million in daily transaction volume. The startup supports Opera’s local apps and services, including motorcycle ride-hail app ORide and OFood delivery. Management says proceeds will be used to grow its digital-finance business in Nigeria and to diversify country and product offerings. The raise is positioned to accelerate mobile-money adoption in Nigeria and strengthen OPay’s compete with other multi-service internet platforms on the continent.

• LakeShore Biopharma

  Participated · Series B · Mar 2021

  YishengBio discovers, develops and commercializes biotherapeutics and vaccines using its PIKA® immunomodulating technology platform. Its commercial product, the YSJA™ alum-free lyophilized rabies vaccine, has been launched in China and provided post-exposure protection to over 16 million patients. The company reports more than 60 patents on PIKA technology across over 30 countries and regions. Its clinical pipeline includes candidates such as YS-ON-001 for advanced solid tumors, YS-HBV-001 for hepatitis B, and PIKA YS-SC2-010 for COVID-19, with other candidates in preclinical and discovery stages. YishengBio operates in China, the USA and Singapore and has over 500 employees. The company plans to expand R&D capacity, accelerate commercialization and advance multiple clinical programs, supported by recent financing to build biologics production facilities in China and Singapore.

No current team members are available.